Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals.
- Author:
Soon Young KO
1
;
Won Hyeok CHOE
Author Information
- Publication Type:Review
- Keywords: Chronic Hepatitis C; Hemodialysis; Direct-acting antivirals
- MeSH: Antiviral Agents*; Comorbidity; Hepacivirus; Hepatitis C*; Hepatitis C, Chronic; Hepatitis*; Humans; Kidney Failure, Chronic; Pharmacokinetics; Renal Dialysis*; Renal Insufficiency, Chronic*
- From:Clinical and Molecular Hepatology 2018;24(4):351-357
- CountryRepublic of Korea
- Language:English
- Abstract: The advent of novel, direct-acting antiviral (DAA) regimens for hepatitis C virus (HCV) infection has revolutionized its treatment by producing a sustained virologic response of more than 95% with few side effects and no comorbidities in the general population. Until recently, ideal DAA regimens have not been available to patients with severe renal impairment and end-stage renal disease because there are limited data on the pharmacokinetics, safety, and efficacy of treatment in this unique population. In a hemodialysis context, identifying patients in need of treatment and preventing HCV transmission may also be a matter of concern. Recently published studies suggest that a combination of paritaprevir/ritonavir/ombitasvir and dasabuvir, elbasvir/grazoprevir, or glecaprevir/pibrentasvir successfully treats HCV infection in chronic kidney disease stage 4 or 5 patients with or without hemodialysis.
